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MODE OF ACTION OF ENOXAPARIN IN PLASMA
Suzette B6guin and H' Coenraad Hemker
Department of Biochemistry' IJniversity of Limburg' Maastricht' The Netherlands
unfractionated heparin in platelet rich plasma acts only on
the lag phase of thrombin producrion and not on the amount
of thiombin produced. Low molecular weight heparins
significantly prolong the lag time and inhibit the thrombin
peak in platelet rich Plasma.
Key words: enoxaparin, low molecular weight hepartn'
thiombin, prothrombinase, platelet Factor 4' feedback
;egulation, Platelet rich Plasma.
Considering the mode of formation of thrombin in
plasma, as it is schematically represented in Fig' I'
it can be seen that an anticoagulant product can act
prothrombin level, or by acting on the components
of the prothrombinase complex, i'e' the activated
Factors X and V on a phospholipid surface'
necessary to inhibit all of these factors to obtain this
anticoagulant treatment.
It is known that unfractionated heparin (UFH)
inhibits theactivated Factors X, IX, XI and thrombin
via its AT III cofactor activity. It has been previously
thromboplastin, as shown in Fig' 4' Its role is
essentialiy that of a catalyst of AT III dependent
thrombin inactivation only. Why does the anti-Xa
property of unfractionated heparin not play a role in
ihe prothrombinase complex inhibition? As shown
in Fig. 3 and as can be seen in Fig. 5' it is necessary
to innibit Factor Xa almost completely, in order to
influence thrombin formation via the inhibit ion of
prothrombinase. [This experiment (Fig' i.) was
carr ied out  by L indhout  and Pieters (3) l '  I t
demonstrates that when the courses of thrombin and
Xa concentration are followed simuluneously in the
same thromboplastin-activated plasma, the thrombi n
peak appears earlier than the Xa peak' During the
iiriii i: rlriulil)iiiiitiiiltl
bi
,kra Chir Scand SuPPI 556
u{r$t*t}iidixmiqririi si
52 S. Biguin and H. C. Hemker
lesion -
Fig. I A scheme of thrombin formation including the feedback mechanisms'
maximum of prothrombin conversion, there is
hardly any Factor Xa present. Therefore, it can be
concluded that only traces of Xa are necessary to
produce a thrombin explosion. Inhibition of Factor
Xa therefore has to be important before it starts
influencing prothrombin conversion.'When in the
presence ofheparin, coagulation is triggered via the
intrinsic pathway (kaolin and phospholipid)- An
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Fig. J. Relationship between prothrombinase activiry and
the concentration of vitamin Kdependent factors'
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Fig. 2. Possible modes of inhibition of coagulation by an
antithrombotic product.
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Fig. 4. Influence of unfractionated heparin on the thrombin and prothrombinase generation 
in thromboplastin activated
pi isma. Control  rH;  hgp311n (U/dj :  O- -O 0.03;  ^H, 0.04;  . -  
- '  0.05;  O-O 0' I '
Time [min]
Fig. 5. Kinetics of thrombin and Factor Xa generation simultaneously measured in thromboplastin activated 
plasma in
rhe presence ofunfractionated heparin and pentasaccharide. Control: ()-o thrombinl H Xa; rH prothrombinase'
Facior Xa generarion: heparin (U)rnl): a- lA O.O5; A- -A 0.01; pentasaccharidet *25 Pglml'
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inhibition of the prothrombinase activity and also a
prolongation of the lag phase before the apparition
of thrombin was observed (l). It can be assumed that
this is because the AT III-heparin complex inhibits
the earliest traces of thrombin (prolongation of the
lag phase) required to convert Factor VIII into Factor
VIIla. Factor VIIIa is required to protect Factor [Xa
from the AT III-heparin inactivation (Fig. 6). In the
absence of Factor VIIIa, Factor IXa (a) can hardly
activate Factor X and (b) is readily inhibited by
AT ll l-heparin. Thus, again, it appears that
thrombin must  be the pr imary target  of  an
anticoagulant product. Because thrombin enhances
its own formation via the mechanism of feedback
reactions (Fig. l), thrombin inhibit ion causes,
secondarily, inhibition of prothrombinase.
Most low molecular weight heparins (LMWHs)
tested are not different from UFH, although their
antiprothrombinase action may be slightly higher' As
shown in Fig.7, enoxaparin inhibits thrombin in a
dose-dependent way. Contrary to most other hep-
arins, it also inhibits the prothrombinase activity in
VWF
vil l
Fig. 6. A scheme of the action of AT III - heparin complex in plasma'
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Fig. 7. lnfluence ofenoxaparin on the generation of
thiombin in plasma via the extrinsic (curves A' B, C) and
intr ins ic (curves D, E,  F)  pathways.  A and D: no hepar in;
B  and  E :0 -6  pg lm l ;  C  and  F :  1 .2  Pg lm l '
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rhe extrinsic pathway (Fig. 8) Why this difference?
enoxapar in is  a mixture;  and when proper ly
Iractionated, two of is major components, fraction
-{ (EMT 966 of relatively high molecular weight)
rnd fraction B (EMT 967 of relatively low molecular
.i,:ight), have been found to possess different prop-
;r ries (2). As summarized in Thble I, fraction A, l ike
{JFH (S type heparin), acts primarily on thrombin
tbrmed and not on prothrombinase. In contrast,
fraction B has no direct effect on thrombin. At high
concentration, it inhibis the prothrombinase com-
plex IP type hepar in (3) ] .
In an attempt to investigate the action in a situ-
rrion nearer to in-vivo circumstances the effect of
rcxaparin and its fractions on thrombin generation
, platelet rich plasma was studied (Fig. 9). As pre-
"; iously found for UFH ( I ) enoxaparin was observed
to induce a prolongation of the lag phase before the
appearance of the thrombin burst. Contrary to UFH,
enoxaparin also inhibits the peak of thrombin. It has
been shown by the authors (1) that up to 0.05 Uiml
of UFH is practically completely inactivated by
activated platelets. This means that UFH in platelet
',:h plasma (PRP) postpones the thrombin burst but
Fig. 9. Inf luence ofenoxaparin and two of i ts major
C,rntrol i  EMT 966;rglml: A 1.3; EMT 961 pglml:
gi ml EMT 967 (recombined enoxaparin).
Mode of uction of enoxaparin 55
Thrombin
o
A
Prothrombinase
7^
A
t' .A
1 2 3 4
Enoxaparin (pg/ml)
Fig.  8.  Thrombin and prothrombinase inhib i t ions by two
batches (whi te and black symbols)  of  enoxapar in in
thromboplast in act ivated plasma. The inhib i t ions are
expressed in per cent of the top of the peak of the
uninhib i ted contro l  run in oaral le l .
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Table l. Inhibition of extrinsic coagulation b'v thc.tu.'o malor
,o^ponrn,, of enoxnparin' The inhibitiotts ara
exp)essed in per cent ofan uninhibited contol nrn in
eventually give the answer'
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lnhib i t ion
(7o )
Concentratton
fuglml) Thrombin Prothrombinase
EMT 966 0.35
(Fraction A) 0.5
EMT 967 5
(Fraction B) l0
60
72
41
19
30
42
64
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active heParin comPonents'
In conclusion, enoxaparin is a mixed type heparin
which inhibits both thrombin and prothrombinase
ase, possibly reinforced by anti-Factor Xa property
of its P tYPe fraction.
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